m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03283)
Name
L-783483
Synonyms
F3MethylAA
    Click to Show/Hide
Status
Investigative
Structure
Formula
C22H21ClF3NO4S
InChI
1S/C22H21ClF3NO4S/c1-2-4-14-17(7-6-15-20(14)31-27-21(15)22(24,25)26)30-9-3-10-32-18-8-5-13(11-16(18)23)12-19(28)29/h5-8,11H,2-4,9-10,12H2,1H3,(H,28,29)
InChIKey
TZBRFAASYWFUGK-UHFFFAOYSA-N
PubChem CID
9935197
TTD Drug ID
D08QXD
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Oxysterols receptor LXR-alpha (NR1H3)
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Oxysterols receptor LXR-alpha (NR1H3) is a therapeutic target for L-783483. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of L-783483 through regulating the expression of Oxysterols receptor LXR-alpha (NR1H3). [1], [2]
Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Peroxisome proliferator-activated receptor gamma (PPAR-gamma) is a therapeutic target for L-783483. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of L-783483 through regulating the expression of Peroxisome proliferator-activated receptor gamma (PPAR-gamma). [3], [4]
References
Ref 1 EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma. Nat Commun. 2021 Jan 8;12(1):177. doi: 10.1038/s41467-020-20379-7.
Ref 2 A natural product ligand of the oxysterol receptor, liver X receptor. J Pharmacol Exp Ther. 2003 Oct;307(1):291-6. doi: 10.1124/jpet.103.052852. Epub 2003 Jul 31.
Ref 3 The m(6)A demethylase FTO promotes the osteogenesis of mesenchymal stem cells by downregulating PPARG. Acta Pharmacol Sin. 2022 May;43(5):1311-1323. doi: 10.1038/s41401-021-00756-8. Epub 2021 Aug 30.
Ref 4 Euglycemic and hypolipidemic activity of PAT5A: a unique thiazolidinedione with weak peroxisome proliferator activated receptor gamma activity. Metabolism. 2000 Nov;49(11):1417-23. doi: 10.1053/meta.2000.17734.